BackgroundMany drugs are used off-label or unlicensed in neonates. This does not mean they are used without evidence or knowledge. We aimed to apply and evaluate the Grading and Assessment of Pharmacokinetic-Pharmacodynamic Studies (GAPPS) scoring system for the level of evidence of two commonly used anti-epileptic drugs.MethodsMidazolam and phenobarbital as anti-epileptics were evaluated with a systematic literature search on neonatal pharmacokinetic (PK) and/or pharmacodynamic [PD, (amplitude-integrated) electroencephalography effect] studies. With the GAPPS system, two evaluators graded the current level of evidence. Inter-rater agreement was assessed for dosing evidence score (DES), quality of evidence (QoE), and strength of recommendation (REC).ResultsSeventy-two studies were included. DES scores 4 and 9 were most frequently used for PK, and scores 0 and 1 for PD. Inter-rater agreements on DES, QoE, and REC ranged from moderate to very good. A final REC was provided for all PK studies, but only for 25% (midazolam) and 33% (phenobarbital) of PD studies.ConclusionsThere is a reasonable level of evidence concerning midazolam and phenobarbital PK in neonates, although using a predefined target without integrated PK/PD evaluation. Further research is needed on midazolam use in term neonates with therapeutic hypothermia, and phenobarbital treatment in preterms.ImpactThere is a reasonable level of evidence concerning pharmacotherapy of midazolam and phenobarbital in neonates. Most evidence is however based on PK studies, using a predefined target level or concentration range without integrated, combined PK/PD evaluation.Using the GAPPS system, final strength of recommendation could be provided for all PK studies, but only for 25% (midazolam) to 33% (phenobarbital) of PD studies.Due to the limited PK observations of midazolam in term neonates with therapeutic hypothermia, and of phenobarbital in preterm neonates these subgroups can be identified for further research.

Grading the level of evidence of neonatal pharmacotherapy: midazolam and phenobarbital as examples / L. Mahoney, G. Raffaeli, S. Beken, S. Ünal, C. Kotidis, G. Cavallaro, F. Garrido, A. Bhatt, E.M. Dempsey, K. Allegaert, S.H.P. Simons, R.B. Flint, A. Smits. - In: PEDIATRIC RESEARCH. - ISSN 0031-3998. - 95:1(2023), pp. 75-83. [10.1038/s41390-023-02779-9]

Grading the level of evidence of neonatal pharmacotherapy: midazolam and phenobarbital as examples

G. Raffaeli;
2023

Abstract

BackgroundMany drugs are used off-label or unlicensed in neonates. This does not mean they are used without evidence or knowledge. We aimed to apply and evaluate the Grading and Assessment of Pharmacokinetic-Pharmacodynamic Studies (GAPPS) scoring system for the level of evidence of two commonly used anti-epileptic drugs.MethodsMidazolam and phenobarbital as anti-epileptics were evaluated with a systematic literature search on neonatal pharmacokinetic (PK) and/or pharmacodynamic [PD, (amplitude-integrated) electroencephalography effect] studies. With the GAPPS system, two evaluators graded the current level of evidence. Inter-rater agreement was assessed for dosing evidence score (DES), quality of evidence (QoE), and strength of recommendation (REC).ResultsSeventy-two studies were included. DES scores 4 and 9 were most frequently used for PK, and scores 0 and 1 for PD. Inter-rater agreements on DES, QoE, and REC ranged from moderate to very good. A final REC was provided for all PK studies, but only for 25% (midazolam) and 33% (phenobarbital) of PD studies.ConclusionsThere is a reasonable level of evidence concerning midazolam and phenobarbital PK in neonates, although using a predefined target without integrated PK/PD evaluation. Further research is needed on midazolam use in term neonates with therapeutic hypothermia, and phenobarbital treatment in preterms.ImpactThere is a reasonable level of evidence concerning pharmacotherapy of midazolam and phenobarbital in neonates. Most evidence is however based on PK studies, using a predefined target level or concentration range without integrated, combined PK/PD evaluation.Using the GAPPS system, final strength of recommendation could be provided for all PK studies, but only for 25% (midazolam) to 33% (phenobarbital) of PD studies.Due to the limited PK observations of midazolam in term neonates with therapeutic hypothermia, and of phenobarbital in preterm neonates these subgroups can be identified for further research.
English
Settore MED/38 - Pediatria Generale e Specialistica
Articolo
Esperti anonimi
Pubblicazione scientifica
Goal 3: Good health and well-being
2023
Springer Nature
95
1
75
83
9
Pubblicato
Periodico con rilevanza internazionale
crossref
pubmed
scopus
wos
Aderisco
info:eu-repo/semantics/article
Grading the level of evidence of neonatal pharmacotherapy: midazolam and phenobarbital as examples / L. Mahoney, G. Raffaeli, S. Beken, S. Ünal, C. Kotidis, G. Cavallaro, F. Garrido, A. Bhatt, E.M. Dempsey, K. Allegaert, S.H.P. Simons, R.B. Flint, A. Smits. - In: PEDIATRIC RESEARCH. - ISSN 0031-3998. - 95:1(2023), pp. 75-83. [10.1038/s41390-023-02779-9]
reserved
Prodotti della ricerca::01 - Articolo su periodico
13
262
Article (author)
Periodico con Impact Factor
L. Mahoney, G. Raffaeli, S. Beken, S. Ünal, C. Kotidis, G. Cavallaro, F. Garrido, A. Bhatt, E.M. Dempsey, K. Allegaert, S.H.P. Simons, R.B. Flint, A. Smits
File in questo prodotto:
File Dimensione Formato  
Mahoney Ped Res 2024.pdf

accesso riservato

Descrizione: Special Article
Tipologia: Publisher's version/PDF
Dimensione 961.39 kB
Formato Adobe PDF
961.39 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1028856
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact